Comparison of Resolute zotarolimus-eluting stents versus everolimus-eluting stents in patients with metabolic syndrome and acute myocardial infarction: propensity score-matched analysis.

[1]  S. Windecker,et al.  Safety and Efficacy of Resolute Zotarolimus-Eluting Stents Compared With Everolimus-Eluting Stents: A Meta-Analysis , 2015, Circulation. Cardiovascular interventions.

[2]  I. Seong,et al.  Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus. , 2014, JACC. Cardiovascular interventions.

[3]  G. Stone,et al.  The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial , 2014, European heart journal. Acute cardiovascular care.

[4]  H. Selker,et al.  Factors Associated With Longer Time to Treatment for Patients With Suspected Acute Coronary Syndromes: A Cohort Study , 2014, Circulation. Cardiovascular quality and outcomes.

[5]  M. Jeong,et al.  One-Year Clinical Outcomes among Patients with Metabolic Syndrome and Acute Myocardial Infarction , 2013, Korean circulation journal.

[6]  M. Jeong,et al.  Association of metabolic syndrome and renal insufficiency with clinical outcome in acute myocardial infarction. , 2013, Metabolism: clinical and experimental.

[7]  M. Banach,et al.  Metabolic syndrome and renal disease. , 2013, International journal of cardiology.

[8]  Nicholas A Peppas,et al.  Recent advances in drug eluting stents. , 2013, International journal of pharmaceutics.

[9]  Mark D. Huffman,et al.  Presentation, management, and outcomes of 25 748 acute coronary syndrome admissions in Kerala, India: results from the Kerala ACS Registry. , 2013, European heart journal.

[10]  Michael J Pencina,et al.  Repeat Revascularization After Contemporary Percutaneous Coronary Intervention: An Evaluation of Staged, Target Lesion, and Other Unplanned Revascularization Procedures During the First Year , 2012, Circulation. Cardiovascular interventions.

[11]  A. Coats,et al.  Adherence to ethical standards in publishing scientific articles: a statement from the International Journal of Cardiology. , 2012, International journal of cardiology.

[12]  Deepak L. Bhatt,et al.  Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents: A Mixed-Treatment Comparison Analysis of 117 762 Patient-Years of Follow-Up From Randomized Trials , 2012, Circulation.

[13]  P. Serruys,et al.  Stent Thrombosis With Everolimus-Eluting Stents: Meta-Analysis of Comparative Randomized Controlled Trials , 2012, Circulation. Cardiovascular interventions.

[14]  J. W. Louwerenburg,et al.  A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. , 2012, Journal of the American College of Cardiology.

[15]  K. Cao,et al.  The angiographic and clinical outcomes after coronary stenting in patients with metabolic syndrome. , 2012, Atherosclerosis.

[16]  P. Serruys,et al.  Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes. , 2012, JACC. Cardiovascular imaging.

[17]  S. Goyal,et al.  Impact of metabolic syndrome on re-stenosis development: Role of drug-eluting stents , 2012, Diabetes & vascular disease research.

[18]  Jong Chun Park,et al.  Comparison of paclitaxel-, sirolimus-, and zotarolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction and metabolic syndrome. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[19]  R. Whitbourn,et al.  Impact of Polymer Formulations on Neointimal Proliferation After Zotarolimus-Eluting Stent With Different Polymers: Insights From the RESOLUTE Trial , 2011, Circulation. Cardiovascular interventions.

[20]  P. Serruys,et al.  The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutan , 2011, Journal of the American College of Cardiology.

[21]  Akiko Maehara,et al.  A prospective natural-history study of coronary atherosclerosis. , 2011, The New England journal of medicine.

[22]  Thomas D. Scott,et al.  Predictors of reperfusion delay in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention from the HORIZONS-AMI trial. , 2010, The American journal of cardiology.

[23]  Lawrence Joseph,et al.  The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. , 2010, Journal of the American College of Cardiology.

[24]  P. Serruys,et al.  Coronary stents: current status. , 2010, Journal of the American College of Cardiology.

[25]  T. Naganuma,et al.  Clinical predictors of culprit plaque rupture assessed on intravascular ultrasound in acute coronary syndrome. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[26]  Volker Klauss,et al.  Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. , 2010, The New England journal of medicine.

[27]  L. Pendyala,et al.  The first-generation drug-eluting stents and coronary endothelial dysfunction. , 2009, JACC. Cardiovascular interventions.

[28]  Ju Han Kim,et al.  Differences in Clinical Outcomes Between Patients With ST-Elevation Versus Non-ST-Elevation Acute Myocardial Infarction in Korea , 2009, Korean circulation journal.

[29]  Qi Zhang,et al.  Impact of moderate or severe renal insufficiency on long-term outcomes in patients undergoing drug-eluting stent based coronary intervention. , 2009, International journal of cardiology.

[30]  G. De Luca,et al.  Percutaneous coronary intervention-related time delay, patient's risk profile, and survival benefits of primary angioplasty vs lytic therapy in ST-segment elevation myocardial infarction. , 2009, The American journal of emergency medicine.

[31]  F. Burzotta,et al.  Metabolic Syndrome Is a Poor Predictor of Outcome after Coronary Interventions in High-Risk Patients , 2008, Hypertension Research.

[32]  P. Macfarlane,et al.  Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies , 2008, The Lancet.

[33]  J. Afilalo,et al.  Symptom-to-door time in ST segment elevation myocardial infarction: overemphasized or overlooked? Results from the AMI-McGill study. , 2008, The Canadian journal of cardiology.

[34]  J. Ottervanger,et al.  The importance of left ventricular function for long-term outcome after primary percutaneous coronary intervention , 2008, BMC Cardiovascular Disorders.

[35]  Y. van der Graaf,et al.  Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. , 2007, European heart journal.

[36]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[37]  Victor M Montori,et al.  Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. , 2007, Journal of the American College of Cardiology.

[38]  H. Burt,et al.  Drug-eluting stents: factors governing local pharmacokinetics. , 2006, Advanced drug delivery reviews.

[39]  Ali H Mokdad,et al.  Increasing prevalence of the metabolic syndrome among u.s. Adults. , 2004, Diabetes care.

[40]  S. Grundy,et al.  The metabolic syndrome , 2003, The Lancet.

[41]  J. Ottervanger,et al.  Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty. , 2004, European heart journal.

[42]  H. Suryapranata,et al.  Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. , 2003, Journal of the American College of Cardiology.

[43]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[44]  J. W. Louwerenburg,et al.  Complex patients treated with zotarolimus‐eluting resolute and everolimus‐eluting xience V stents in the randomized TWENTE trial: Comparison of 2‐year clinical outcome , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[45]  J. Baron,et al.  World Wide Web at: , 2001 .